OnKure Therapeutics (OKUR) News Today $8.61 -0.12 (-1.37%) (As of 12/18/2024 05:44 PM ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesSEC FilingsTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period Oppenheimer Remains a Buy on OnKure Therapeutics (OKUR)December 12, 2024 | markets.businessinsider.comOnKure Therapeutics announces safety, pharmacokinetic data on OKI-219December 11, 2024 | markets.businessinsider.comOnKure Therapeutics Reports Positive Preliminary Data From First-in-human Study Of OKI-219December 10, 2024 | markets.businessinsider.comOnKure Therapeutics Advances Cancer Drug TrialsDecember 10, 2024 | tipranks.comOnKure Announces Encouraging Preliminary Safety, Tolerability, and Pharmacokinetic (PK) Data from its First-In-Human PIKture-01 Trial of OKI-219December 10, 2024 | globenewswire.comWhat is Leerink Partnrs' Estimate for OKUR FY2024 Earnings?December 10, 2024 | americanbankingnews.comLeerink Partners Initiates Coverage of OnKure Therapeutics (OKUR) with Outperform RecommendationDecember 5, 2024 | msn.comOnKure Therapeutics Inc Class A SharesDecember 5, 2024 | morningstar.comOnKure Therapeutics Reports Strategic Merger and Financial UpdatesNovember 26, 2024 | markets.businessinsider.comOnKure Announces New Date for Upcoming Investor CallNovember 25, 2024 | globenewswire.comOnKure Therapeutics Faces Post-Merger Hurdles: Integration Challenges and Talent Competition Threaten GrowthNovember 9, 2024 | tipranks.comOnKure Therapeutics' (OKUR) "Buy" Rating Reiterated at HC WainwrightHC Wainwright reiterated a "buy" rating and set a $40.00 price target on shares of OnKure Therapeutics in a report on Friday.November 8, 2024 | marketbeat.comOnKure to Present Clinical and Preclinical Data for OKI-219 at the 2024 San Antonio Breast Cancer SymposiumNovember 1, 2024 | globenewswire.comQ3 Earnings Forecast for OKUR Issued By HC WainwrightOnKure Therapeutics (NASDAQ:OKUR - Free Report) - Analysts at HC Wainwright issued their Q3 2024 earnings estimates for OnKure Therapeutics in a report released on Thursday, October 17th. HC Wainwright analyst R. Burns anticipates that the company will earn ($1.03) per share for the quarter. HC WOctober 21, 2024 | marketbeat.comWhat is HC Wainwright's Estimate for OKUR Q1 Earnings?OnKure Therapeutics (NASDAQ:OKUR - Free Report) - Equities researchers at HC Wainwright issued their Q1 2025 earnings per share estimates for OnKure Therapeutics in a research report issued on Thursday, October 17th. HC Wainwright analyst R. Burns anticipates that the company will post earnings oOctober 18, 2024 | marketbeat.comOnKure Therapeutics (NASDAQ:OKUR) Earns Buy Rating from HC WainwrightHC Wainwright reissued a "buy" rating and issued a $40.00 price objective on shares of OnKure Therapeutics in a research report on Thursday.October 17, 2024 | marketbeat.com Get OnKure Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for OKUR and its competitors with MarketBeat's FREE daily newsletter. Email Address Has Trump Finally Gone Too Far? (Ad)Lately, there's been a lot of buzz around a secret loophole executive insiders are using to make millions buying and selling their own stocks. It's so powerful ... so profitable ... that most people immediately assume this is just another example of Trump doing what's best for business executives. But surprisingly, this loophole has been on the books for many years and executives have been using it to make HUNDREDS of millions of dollars. And here's the good news. Register For The Webinar To Discover OKUR Media Mentions By Week OKUR Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. OKUR News Sentiment▼0.810.45▲Average Medical News Sentiment OKUR News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. OKUR Articles This Week▼12▲OKUR Articles Average Week Get OnKure Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for OKUR and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Acrivon Therapeutics News Amarin News Trevi Therapeutics News XBiotech News 2seventy bio News Checkpoint Therapeutics News Corbus Pharmaceuticals News Nektar Therapeutics News LifeVantage News PepGen News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:OKUR) was last updated on 12/19/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTop Picks for Trump’s Pro-Crypto AmericaCoins Set to Soar with a Pro-Crypto White House President-Elect Donald Trump is reported to be holding over...Crypto 101 Media | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding OnKure Therapeutics Please log in to your account or sign up in order to add this asset to your watchlist. Share OnKure Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free OKUR Stock Alerts